DexCom, Inc. (DXCM) analyst actions
Rating and price-target actions on DXCM in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the DXCM overview →
2 measured DXCM analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against DexCom, Inc. (DXCM) And Encourages Shareholders to Reach Out | Press release | +0.24% | +1.59% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against DexCom, Inc. (DXCM) And Encourages Stockholders to Reach Out | Press release | +0.64% | -0.22% |
Keep exploring
More DXCM: earnings → · SEC filings → · DXCM overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| AETNA (AET) | 2,000+ | +0.06% | 58% |
| ALLERGAN INC (AGN) | 2,000+ | +0.04% | 54% |
| Endo International plc - Ordinary Shares (ENDP) | 2,000+ | 0.00% | 49% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2,000+ | +0.11% | 56% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.